Mississauga, ON -- (SBWIRE) -- 10/15/2015 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled "PharmaCyte Biotech Shares Rise As Next Clinical Trial for Pancreatic Cancer is Designed."
Companies mentioned in this article include Aduro Biotech (NASDAQ:ADRO) and PharmaCyte Biotech Inc. (OTCQB:PMCB).
Pancreatic cancer is a nightmare. Even with the current "gold standard" treatment of gemcitabine and nab-paclitaxel (Abraxane®), the American Cancer Society lists the five-year survival rate (the percentage of patients that live at least five years after diagnoses) for patients diagnosed at Stage 1A (early stage) as only 14 percent. As with most cancers, the later the cancer is found, the lower the five-year survival rate. In the case of Stage 4 patients, only 1 percent live at least another half-decade.
Companies are looking for innovative ways to treat pancreatic cancer, a disease that is often silent in onset and resulted in about 40,500 deaths in 2014, according to Cancer.net. Making matters worse, there are no specific, cost-effective screening tests to easily and reliably detect early stage disease in people showing no symptoms. Aduro Biotech (NASDAQ:ADRO) is targeting several types of cancer in its immunotherapy pipeline, including two, separate mid-stage trials of its CRS-207; one in combination with GVAX alone and another with GVAX plus the checkpoint inhibitor nivolumab for pancreatic cancer.
The full version of this article can be found at:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999.
Investors can receive their free newsletter subscription by clicking here:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.